Logo image of ITCI

INTRA-CELLULAR THERAPIES INC (ITCI) Stock Fundamental Analysis

NASDAQ:ITCI - Nasdaq - US46116X1019 - Common Stock - Currency: USD

126.99  +0.09 (+0.07%)

Fundamental Rating

5

Overall ITCI gets a fundamental rating of 5 out of 10. We evaluated ITCI against 195 industry peers in the Pharmaceuticals industry. ITCI has a great financial health rating, but its profitability evaluates not so good. ITCI is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ITCI has reported negative net income.
ITCI had a negative operating cash flow in the past year.
In the past 5 years ITCI always reported negative net income.
ITCI had a negative operating cash flow in each of the past 5 years.
ITCI Yearly Net Income VS EBIT VS OCF VS FCFITCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M -250M

1.2 Ratios

ITCI has a better Return On Assets (-6.52%) than 75.27% of its industry peers.
With a decent Return On Equity value of -7.54%, ITCI is doing good in the industry, outperforming 78.49% of the companies in the same industry.
Industry RankSector Rank
ROA -6.52%
ROE -7.54%
ROIC N/A
ROA(3y)-37.04%
ROA(5y)-40.31%
ROE(3y)-43.55%
ROE(5y)-48.19%
ROIC(3y)N/A
ROIC(5y)N/A
ITCI Yearly ROA, ROE, ROICITCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

ITCI has a Gross Margin of 92.30%. This is amongst the best in the industry. ITCI outperforms 96.24% of its industry peers.
In the last couple of years the Gross Margin of ITCI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ITCI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5YN/A
ITCI Yearly Profit, Operating, Gross MarginsITCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50K -100K -150K

More info and screens

8

2. Health

2.1 Basic Checks

ITCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
ITCI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ITCI has been increased compared to 5 years ago.
There is no outstanding debt for ITCI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ITCI Yearly Shares OutstandingITCI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
ITCI Yearly Total Debt VS Total AssetsITCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 44.33 indicates that ITCI is not in any danger for bankruptcy at the moment.
ITCI's Altman-Z score of 44.33 is amongst the best of the industry. ITCI outperforms 96.24% of its industry peers.
ITCI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 44.33
ROIC/WACCN/A
WACC9.57%
ITCI Yearly LT Debt VS Equity VS FCFITCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 7.66 indicates that ITCI has no problem at all paying its short term obligations.
ITCI has a Current ratio of 7.66. This is in the better half of the industry: ITCI outperforms 77.96% of its industry peers.
A Quick Ratio of 7.51 indicates that ITCI has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.51, ITCI is in the better half of the industry, outperforming 79.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.66
Quick Ratio 7.51
ITCI Yearly Current Assets VS Current LiabilitesITCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

ITCI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.96%, which is quite impressive.
Looking at the last year, ITCI shows a very strong growth in Revenue. The Revenue has grown by 46.06%.
ITCI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 173.09% yearly.
EPS 1Y (TTM)45.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)46.06%
Revenue growth 3Y173.09%
Revenue growth 5YN/A
Sales Q2Q%39%

3.2 Future

The Earnings Per Share is expected to grow by 57.70% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 41.14% on average over the next years. This is a very strong growth
EPS Next Y50.93%
EPS Next 2Y50.26%
EPS Next 3Y65.07%
EPS Next 5Y57.7%
Revenue Next Year44.35%
Revenue Next 2Y41.19%
Revenue Next 3Y45.11%
Revenue Next 5Y41.14%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ITCI Yearly Revenue VS EstimatesITCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B
ITCI Yearly EPS VS EstimatesITCI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10 15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ITCI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
ITCI is valuated quite expensively with a Price/Forward Earnings ratio of 337.33.
Based on the Price/Forward Earnings ratio, ITCI is valued a bit cheaper than the industry average as 71.51% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 92.74. ITCI is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 337.33
ITCI Price Earnings VS Forward Price EarningsITCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 -100 200 300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ITCI Per share dataITCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ITCI does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as ITCI's earnings are expected to grow with 65.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.26%
EPS Next 3Y65.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ITCI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTRA-CELLULAR THERAPIES INC

NASDAQ:ITCI (2/5/2025, 9:48:50 AM)

126.99

+0.09 (+0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30 2024-10-30/bmo
Earnings (Next)02-26 2025-02-26/amc
Inst Owners95.22%
Inst Owner Change-0.41%
Ins Owners0.21%
Ins Owner Change0%
Market Cap13.46B
Analysts83.64
Price Target128.71 (1.35%)
Short Float %1.47%
Short Ratio0.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.74%
Min EPS beat(2)-24.97%
Max EPS beat(2)17.5%
EPS beat(4)3
Avg EPS beat(4)19.17%
Min EPS beat(4)-24.97%
Max EPS beat(4)50.59%
EPS beat(8)7
Avg EPS beat(8)26.22%
EPS beat(12)9
Avg EPS beat(12)19.65%
EPS beat(16)11
Avg EPS beat(16)16.35%
Revenue beat(2)1
Avg Revenue beat(2)-0.01%
Min Revenue beat(2)-0.24%
Max Revenue beat(2)0.22%
Revenue beat(4)2
Avg Revenue beat(4)-1.03%
Min Revenue beat(4)-4.54%
Max Revenue beat(4)0.45%
Revenue beat(8)5
Avg Revenue beat(8)0.27%
Revenue beat(12)9
Avg Revenue beat(12)1.92%
Revenue beat(16)11
Avg Revenue beat(16)1.4%
PT rev (1m)21.91%
PT rev (3m)31.2%
EPS NQ rev (1m)-1.1%
EPS NQ rev (3m)-142.96%
EPS NY rev (1m)-0.74%
EPS NY rev (3m)-3.5%
Revenue NQ rev (1m)0.28%
Revenue NQ rev (3m)3.23%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)1.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 337.33
P/S 21.94
P/FCF N/A
P/OCF N/A
P/B 11.76
P/tB 11.76
EV/EBITDA N/A
EPS(TTM)-0.87
EYN/A
EPS(NY)0.38
Fwd EY0.3%
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS5.79
BVpS10.8
TBVpS10.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.52%
ROE -7.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.3%
FCFM N/A
ROA(3y)-37.04%
ROA(5y)-40.31%
ROE(3y)-43.55%
ROE(5y)-48.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5YN/A
F-Score4
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 139.29%
Cap/Sales 0.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.66
Quick Ratio 7.51
Altman-Z 44.33
F-Score4
WACC9.57%
ROIC/WACCN/A
Cap/Depr(3y)77.13%
Cap/Depr(5y)85.63%
Cap/Sales(3y)0.25%
Cap/Sales(5y)140.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y50.93%
EPS Next 2Y50.26%
EPS Next 3Y65.07%
EPS Next 5Y57.7%
Revenue 1Y (TTM)46.06%
Revenue growth 3Y173.09%
Revenue growth 5YN/A
Sales Q2Q%39%
Revenue Next Year44.35%
Revenue Next 2Y41.19%
Revenue Next 3Y45.11%
Revenue Next 5Y41.14%
EBIT growth 1Y29.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37%
EBIT Next 3Y55.63%
EBIT Next 5Y67.01%
FCF growth 1Y79.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y79.56%
OCF growth 3YN/A
OCF growth 5YN/A